FTC Continues To Zero In On Problematic M&A Noncompetes

By and on May 28, 2020

Since September 2019, the Federal Trade Commission has challenged noncompete provisions in at least three transactions. These challenges demonstrate that the FTC will challenge noncompete provisions even when it concludes that the underlying transaction raises no substantive antitrust issues and when the provision relates to
minority investments.

Noncompete provisions help protect a buyer’s significant investment in an acquired business by restricting the seller from turning around and starting a new business that devalues the business sold. Although noncompete clauses often play a vital role in mergers and acquisitions, they are not immune from antitrust scrutiny. The recent challenges to noncompete provisions show that the FTC and other antitrust enforcers are closely scrutinizing noncompetes and will not hesitate to challenge problematic provisions — whether standalone or as part of a larger challenge to a transaction.

Parties to a commercial transaction, however, can easily manage these risks by carefully tailoring the scope of the noncompete to the transaction at hand. This article reviews recent enforcement actions involving noncompetes and provides practical guidance for mitigating antitrust risk associated with these valuable provisions.

Access Full Article

Joel R. GrosbergJoel R. Grosberg
Joel R. Grosberg defends clients on mergers, acquisitions and joint ventures before the Federal Trade Commission (FTC), Department of Justice, state antitrust authorities, foreign competition authorities, as well as on antitrust litigation. Joel has significant experience in the high tech, chemical, health care and life sciences industries, including counseling on matters related to pricing and distribution practices and other competition-related issues. Read Joel Grosberg's full bio.


Lisa P. RuminLisa P. Rumin
Lisa P. Rumin focuses her practice on antitrust, regulatory and litigation matters. She assists clients across a variety of industries and has represented numerous clients in the healthcare, pharmaceutical, and biotechnology industries. Lisa advises clients on mergers and acquisitions, including obtaining clearance from the Federal Trade Commission (FTC) and Department of Justice (DOJ), as well as counsels clients on issues regarding antitrust compliance, pricing, and distribution. Read Lisa Rumin's full bio here. 

STAY CONNECTED

TOPICS

ARCHIVES